Does Remibrutinib Interact with Acetyl Salicylic Acid?
CDI records a moderate classification for Remibrutinib and Acetyl Salicylic Acid. The stored summary is: Doses up to 100 mg daily were allowed in clinical studies. Consider risks and benefits of concomitant antithrombotic use. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Remibrutinib Class
- Kinase Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
What To Tell Your Doctor or Pharmacist
If you are taking Remibrutinib and your doctor is considering prescribing Acetyl Salicylic Acid (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider